PT743856E - Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros - Google Patents

Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros

Info

Publication number
PT743856E
PT743856E PT95912577T PT95912577T PT743856E PT 743856 E PT743856 E PT 743856E PT 95912577 T PT95912577 T PT 95912577T PT 95912577 T PT95912577 T PT 95912577T PT 743856 E PT743856 E PT 743856E
Authority
PT
Portugal
Prior art keywords
heteropolymes
antigen
auto
treatment
those
Prior art date
Application number
PT95912577T
Other languages
English (en)
Inventor
Ronald P Taylor
Polly J Ferguson
Edward N Martin
Craig J Reist
Kirsten Greene
Cyd Johnson
William S Sutherland
Original Assignee
Univ Virginia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia filed Critical Univ Virginia
Publication of PT743856E publication Critical patent/PT743856E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT95912577T 1994-02-28 1995-02-28 Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros PT743856E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20257294A 1994-02-28 1994-02-28

Publications (1)

Publication Number Publication Date
PT743856E true PT743856E (pt) 2003-12-31

Family

ID=22750436

Family Applications (1)

Application Number Title Priority Date Filing Date
PT95912577T PT743856E (pt) 1994-02-28 1995-02-28 Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros

Country Status (11)

Country Link
US (2) US5879679A (pt)
EP (1) EP0743856B1 (pt)
JP (1) JPH09509572A (pt)
AT (1) ATE245030T1 (pt)
AU (1) AU696964B2 (pt)
CA (1) CA2183535A1 (pt)
DE (1) DE69531290T2 (pt)
DK (1) DK0743856T3 (pt)
ES (1) ES2207646T3 (pt)
PT (1) PT743856E (pt)
WO (1) WO1995022977A1 (pt)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0743856B1 (en) * 1994-02-28 2003-07-16 The University Of Virginia Patent Foundation Antigen-based heteropolymers for treating autoimmune diseases
WO2001041813A2 (en) * 1999-11-28 2001-06-14 La Jolla Pharmaceutical Company Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
AU4155602A (en) * 2000-11-01 2002-06-18 Elusys Therapeutics Inc Method of producing biospecific molecules by protein trans-splicing
JP2004532626A (ja) * 2001-03-15 2004-10-28 エリューシス セラピューティクス,インコーポレーテッド 二重特異性分子のポリクローナル集団、ならびにそれらの産生方法および使用
EP1416945A4 (en) * 2001-07-17 2006-02-22 Univ Virginia IMPROVED HETEROPOLYMER COMPLEXES AND METHODS FOR THEIR USE
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US7378094B2 (en) * 2001-08-29 2008-05-27 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
WO2003095626A2 (en) * 2002-05-13 2003-11-20 Elusys Therapeutics, Inc. Purified composition of bispecific molecules and methods of production
WO2003106695A2 (en) * 2002-06-13 2003-12-24 Cygene, Inc. Methods and compositions for in vivo clearance of pathogens
CA2499081A1 (en) * 2002-09-16 2004-04-22 Elusys Therapeutics, Inc. Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
AU2003303524A1 (en) * 2002-12-27 2004-07-29 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
JP2007525446A (ja) * 2003-03-28 2007-09-06 エルシス セラピューティクス, インク. 抗体活性の転換のための方法及び組成物
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
CA2524771A1 (en) 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (cr1) molecules on erythrocytes and uses therefor
US9493538B2 (en) * 2004-05-28 2016-11-15 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
EP1814918A1 (en) * 2004-10-29 2007-08-08 Elusys Therapeutics, Inc. Use of cr1-binding molecules in clearance and induction of immune responses
EP1945261A4 (en) 2005-11-07 2010-05-12 Scripps Research Inst COMPOSITIONS AND METHODS FOR CONTROLLING THE SPECIFICITY OF TISSUE FACTOR SIGNALING
US8828077B2 (en) * 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
JP6017422B2 (ja) 2010-08-10 2016-11-02 エコール・ポリテクニーク・フェデラル・ドゥ・ローザンヌ(ウペエフエル)Ecole Polytechnique Federale de Lausanne (EPFL) 赤血球結合療法
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
FR2968304B1 (fr) * 2010-12-01 2014-03-14 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux epaississants cationiques, exempts d'huile et de tensioactifs, procede pour leur preparation et composition en contenant.
SG11201404943PA (en) * 2012-02-15 2014-10-30 Ecole Polytech Erythrocyte-binding therapeutics
AU2015233084B2 (en) 2014-02-21 2020-12-17 Anokion Sa Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
CA3079014A1 (en) * 2017-10-20 2019-04-25 Csl Ltd. Method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
EP0743856B1 (en) * 1994-02-28 2003-07-16 The University Of Virginia Patent Foundation Antigen-based heteropolymers for treating autoimmune diseases

Also Published As

Publication number Publication date
ATE245030T1 (de) 2003-08-15
US5879679A (en) 1999-03-09
WO1995022977A1 (en) 1995-08-31
DE69531290T2 (de) 2004-05-13
ES2207646T3 (es) 2004-06-01
DE69531290D1 (de) 2003-08-21
US20020103343A1 (en) 2002-08-01
CA2183535A1 (en) 1995-08-31
AU696964B2 (en) 1998-09-24
JPH09509572A (ja) 1997-09-30
EP0743856A4 (en) 2000-04-12
EP0743856A1 (en) 1996-11-27
DK0743856T3 (da) 2003-11-10
EP0743856B1 (en) 2003-07-16
AU1967795A (en) 1995-09-11

Similar Documents

Publication Publication Date Title
PT743856E (pt) Heteropolimeros a base de antigenes e metodo para o tratamento de doencas auto-imunes utilizando esses heteropolimeros
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ES2106195T3 (es) Anticuerpo igg aglicosilado anti cd3.
DK1194167T3 (da) Immunoterapi af autoimmune sygdomme under anvendelse af B-cellespecifikke antistoffer
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
FI963004A0 (fi) Vasta-aineen muodostumista kiihottavia monoklonaalivasta-aineita
DK0812333T3 (da) Bispecifikt antistof, som er effektivt til behandling af B-cellelymfom og cellelinie
DK0826696T3 (da) Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
ATE273388T1 (de) Veränderte menschliche c3-proteine
DE69522689D1 (de) Zellzyklus-unabhängige, gliomaoberflach-spezifische, menschliche monoklonale antikörper
PT89573A (pt) Metodo para a reducao de respostas mediadas por imunoglobulina e
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
FI973484A (fi) Menetelmä immuunivasteen stimuloimiseksi
SE8800886L (sv) Immunglobulinkojugat
PT733903E (pt) Processo de dosagem imunologica de cortisol nomeadamente urinario e reagentes utilizados
Greiner et al. The Pivotal Role of the Immunoglobulin Receptor of Tumor Cells Fron B Cell Lymphomas of Mucosa Associated Lymphoid Tissue (MALT)
ES552073A0 (es) Un procedimiento para purificar urocinasa